Daraxonrasib combined with chemotherapy produced substantial tumour shrinkage in patients with metastatic pancreatic cancer, according to updated early-stage trial results presented in Barcelona, Spain, on Friday, November 20, 2026.
The findings from the phase 1/2 RMC-GI-102 study showed that 60.7 per cent of 61 patients responded to the treatment combination, including complete responses in 8.2 per cent of participants whose tumours were no longer detectable on scans.
The results are encouraging because metastatic pancreatic cancer is aggressive and has historically responded poorly to treatment.
However, the study was not designed to compare the combination directly with chemotherapy alone, meaning the results do not yet establish that daraxonrasib improves survival over current first-line treatment.
Table of Contents
What the daraxonrasib trial found
Participants in the trial received 200 milligrams of daraxonrasib once daily along with gemcitabine and nab-paclitaxel, two chemotherapy medicines delivered by intravenous infusion on days 1 and 15 of each treatment cycle.
As of September 28, 2026, the 61 patients had been followed for a median of 18.3 months.
- Confirmed objective response rate: 60.7 per cent
- Complete response rate: 8.2 per cent
- Disease control rate: 90.2 per cent
- Median progression-free survival: 12.8 months
- Median duration of response: 11.1 months
- Patients alive at 12 months: 76.6 per cent
Progression-free survival measures the time before cancer grows or a new cancer site appears.
It does not mean that a patient has been cured.
The study results were presented by Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center, during a late-breaking session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
The conference organizers said the combination produced deeper responses and longer disease control than has typically been seen with chemotherapy in this setting, while also emphasizing that the results need to be tested in a randomized phase 3 study.
How daraxonrasib works
Daraxonrasib, sold in the United States under the brand name RASONQUE, is an oral RAS inhibitor designed to interfere with the active form of RAS proteins that help cancer cells grow and survive.
RAS mutations are found in more than 90 per cent of pancreatic cancers, according to the conference materials, making the pathway a major target for drug developers.
Researchers have spent decades trying to target RAS effectively because the proteins were considered difficult to block without also damaging healthy cells.
The trial combination is intended to attack the disease in two ways by pairing a targeted treatment with established chemotherapy medicines.
Why the results require caution
The RMC-GI-102 study was an open-label phase 1/2 trial, and patients were not randomly assigned to receive either the drug combination or chemotherapy alone.
That design makes it difficult to determine how much of the reported response came from daraxonrasib, how much came from chemotherapy, and how much may reflect differences among the patients enrolled in the study.
The conference organizers said the next step is a global phase 3 trial known as RASolute 303, which is comparing daraxonrasib alone and daraxonrasib combined with gemcitabine and nab-paclitaxel against gemcitabine and nab-paclitaxel alone in patients who have not previously received treatment for metastatic disease.
A larger randomized study will also provide a more reliable test of overall survival, side effects and the duration of benefit.
Revolution Medicines, which sponsored the study, said the updated results support the ongoing phase 3 programme and the further evaluation of daraxonrasib as a potential first-line treatment.
Daraxonrasib already has a narrower approval
The U.S. Food and Drug Administration approved daraxonrasib on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic treatment or who are not candidates for multi-agent systemic therapy.
That approval was based on the randomized RASolute 302 trial involving 500 patients whose metastatic pancreatic cancer had progressed after one previous line of systemic treatment.
In that study, median overall survival was 13.2 months for patients receiving daraxonrasib, compared with 6.7 months for those receiving the physician’s choice of standard chemotherapy.
Median progression-free survival was 7.2 months with daraxonrasib and 3.6 months with standard chemotherapy, while the objective response rate was 30 per cent and 11 per cent, respectively.
The approved U.S. dose is 300 milligrams taken orally once daily until the disease progresses or side effects become unacceptable.
The FDA lists warnings involving skin and soft-tissue toxicity, mouth inflammation and other oral disorders, diarrhoea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and embryo-fetal toxicity.
Commonly reported side effects include rash, diarrhoea, stomatitis, nausea, fatigue, vomiting, abdominal pain, swelling, reduced appetite and bleeding.
What happens next
The phase 3 RASolute 303 trial will determine whether the promising response rates from the early study translate into longer survival and a meaningful improvement over standard chemotherapy.
Until those results are available, the new findings should be viewed as an encouraging research signal rather than proof that daraxonrasib can eliminate pancreatic cancer.
Patients with pancreatic cancer should speak with their oncology team about approved treatment options and whether a suitable clinical trial is available for their diagnosis, mutation profile and previous treatment history.
Frequently Asked Questions
What is daraxonrasib?
Daraxonrasib is an oral RAS inhibitor sold in the United States under the brand name RASONQUE. It is designed to block cancer-driving RAS signals.
How effective was daraxonrasib in the new pancreatic cancer trial?
In the updated phase 1/2 study, 60.7 per cent of 61 patients responded when daraxonrasib was combined with gemcitabine and nab-paclitaxel. Complete responses occurred in 8.2 per cent of patients.
Does daraxonrasib cure pancreatic cancer?
No. The early trial found that some tumours became undetectable, but the study was not designed to prove a cure and longer follow-up is needed.
Is daraxonrasib approved for pancreatic cancer?
The U.S. FDA approved daraxonrasib for certain adults with metastatic pancreatic adenocarcinoma after previous systemic therapy, or for patients unable to receive multi-agent systemic treatment.
What is the next step for daraxonrasib research?
The phase 3 RASolute 303 trial is comparing daraxonrasib alone and in combination with chemotherapy against chemotherapy alone as an initial treatment for metastatic pancreatic cancer.
Fact-Checked: Key trial results, regulatory details, treatment eligibility and safety information were checked against the EORTC-NCI-AACR announcement, Revolution Medicines data and U.S. FDA approval records.
Disclaimer: This article is for general information only and is not medical advice or a substitute for guidance from a qualified oncology professional.